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Abstract
Background: Upregulation of endogenous angiostatin levels may constitute a novel anti-
angiogenic, and therefore anti-tumor therapy. In vitro, angiostatin generation is a two-step process,
starting with the conversion of plasminogen to plasmin by plasminogen activators (PAs). Next,
plasmin excises angiostatin from other plasmin molecules, a process requiring a donor of a free
sulfhydryl group. In previous studies, it has been demonstrated that administration of PA in
combination with the free sulfhydryl donor (FSD) agents captopril or N-acetyl cysteine, resulted in
angiostatin generation, and anti-angiogenic and anti-tumour activity in murine models.
Methods: In this study we have investigated the angiostatin generating capacities of several FSDs.
D-penicillamine proved to be most efficient in supporting the conversion of plasminogen to
angiostatin in vitro. Next, from the optimal concentrations of tPA and D-penicillamine in vitro,
equivalent dosages were administered to healthy Balb/c mice to explore upregulation of circulating
angiostatin levels. Finally, anti-tumor effects of treatment with tPA and D-penicillamine were
determined in a human melanoma xenograft model.
Results: Surprisingly, we found that despite the superior angiostatin generating capacity of D-
penicillamine in vitro, both in vivo angiostatin generation and anti-tumour effects of tPA/D-
penicillamine treatment were impaired compared to our previous studies with tPA and captopril.
Conclusion: Our results indicate that selecting the most appropriate free sulfhydryl donor for
anti-angiogenic therapy in a (pre)clinical setting should be performed by in vivo rather than by in vitro
studies. We conclude that D-penicillamine is not suitable for this type of therapy.
Background
Angiogenesis is an essential step in both tumour growth
and the formation of distant metastases. Therefore, inhi-
bition of tumour angiogenesis is currently being explored
as a novel anti-tumour treatment [1-5].
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One class of anti-angiogenic compounds consists of pro-
teolytic fragments of larger parent molecules. Examples of
this type of angiogenesis inhibitors are angiostatin and
endostatin, that are fragments of plasminogen and colla-
gen XVIII, respectively [6,7]
Angiostatin has been shown to possess anti-angiogenic
effects both in vitro and in vivo. In vitro, angiostatin inhib-
ited endothelial cell migration, proliferation and tube for-
mation [8-13]. In vivo, administration of angiostatin –
either alone, or in combination with radiotherapy or
chemotherapy – resulted in potent inhibition of tumour
growth and metastasis formation in several animal
tumour models [14,14-19].
Application of naturally occurring anti-angiogenic mole-
cules in a clinical setting may be especially attractive, as
these compounds have been shown to combine limited
toxicity with the absence of development of drug resist-
ance in several animal tumour models [20,16]. The step
from animal model to clinical application, however, has
in the case of angiostatin been hampered by problems
associated with producing sufficient amounts of biologi-
cally active recombinant protein. In addition, several dif-
ferent angiostatin moieties have been described, possibly
with different clinical efficacies [9,21,22]. As angiostatin is
also present in the circulation of healthy individuals [11];
Westphal, manuscript in preparation], boosting the angi-
ostatin generating capacities of the host might provide an
alternative for exogenous angiostatin administration.
In vitro, angiostatin is generated via a two-step process
[23]. First, plasminogen activators (PAs) convert plas-
minogen into the active protease plasmin. Next, plasmin
excises angiostatin from other plasmin molecules or from
plasminogen, in a process requiring a donor of a free sulf-
hydryl (-SH) group (FSD). In several recent studies,
administration of tissue type plasminogen activator (tPA)
and/or a FSD has actually been shown to result in anti-
angiogenic activity in vitro and additional anti-tumour
activity in murine models. Merchan et al. reported that
human plasma treated with tPA and captopril displayed
anti-angiogenic activity in an in vitro tube formation assay.
In vivo, tPA/captopril treatment inhibited angiogenesis in
Matrigel plugs. In addition, anti-angiogenic activity was
present in serum from human cancer patients treated with
tPA and captopril. Remarkably, the anti-angiogenic activ-
ity present in the plasma samples was not completely
attributable to angiostatin, as plasma, from which angi-
ostatin was depleted, retained its anti-angiogenic proper-
ties [24]. Agarwal et al [25] showed that administration of
the FSD N-acetyl-cysteine to MDA-MB-435 breast carci-
noma xenograft bearing mice resulted in angiostatin accu-
mulation in the tumour, the induction of apoptosis in
endothelial cells, a reduction of vascular density in the
core of the tumour and, as a consequence, a reduced
tumour growth rate. Studies performed in our laboratory
have demonstrated that administration of tPA in combi-
nation with captopril to mice resulted in an increased
level of circulating angiostatin. In addition, this treatment
resulted in anti-tumor activity in a human melanoma
xenograft model [26]. Finally, Soff reported potent anti-
tumour activity in human cancer patients after treatment
with uPA and captopril [27].
However, several questions remain to be addressed. Most
FSDs have other characteristics beside their capability to
donate a SH group that may interfere with their applica-
tion in the clinical setting. Moreover, these properties may
influence, either positively or negatively, their angiostatin
generating capacity. Captopril, for instance, is a potent
ACE inhibitor, and administration of captopril lowers the
blood pressure. Impaired blood flow towards and in the
tumour may have contributed to the observed reduction
in tumour growth. In addition, captopril inhibits matrix
metalloproteinases [28,29], molecules that are promi-
nently involved in angiogenesis [30].
N-acetyl-cysteine (NAC), a glutathione precursor and FSD
used in the study by Agarwal et al [25], not only affects
angiostatin formation, but also possesses antioxidant
activity, and inhibits MMPs [31]. Clearly, there is a need
for preclinical studies to determine the net effects of the
FSDs, and to select the FSD that is best suited for clinical
studies.
In this paper we have compared the in vitro angiostatin
generating capacities of a panel of FSDs. In our hands, D-
penicillamine, a structural analog of cysteine, displayed a
higher angiostatin generating capacity on a molar basis
than either captopril, NAC, or other FSDs. Next, we mon-
itored circulating angiostatin levels in mice treated with
D-penicillamine and tPA, and, finally, we assessed the
anti-tumour activity of the FSD/plasminogen activator
treatment in an human melanoma xenograft model. Sur-
prisingly, the superior in vitro angiostatin generation
capacity of D-penicillamine was not reflected in either
efficient in vivo angiostatin generation or superior anti-
tumour activity. In both assays, D-penicillamine was less
effective than captopril, indicating the need for further
research into the most optimal free sulfhydryl group
donor for clinical applications.
Methods
Angiostatin formation in vitro
uPA (Sigma-Aldrich Chemie b.v., Zwijndrecht, The Nether-
lands) or tPA(Actilyse, Boehringer Ingelheim b.v., Alkmaar,
The Netherlands) and/or free sulfhydryl donor D-penicilla-
mine, L-cysteine, N-acetyl-L-cysteine, reduced glutathione
(Sigma-Aldrich Chemie bv., Zwijndrecht, The Netherlands) or
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captopril (Bristol-Myers Squibb B.V., Woerden, The Nether-
lands) were incubated with murine serum (diluted 1:40 in
sterile distilled water) at 37°C for 0, 2, 4.5 or 20 hours.
Different concentrations of each compound were tested.
Angiostatin generation was analyzed by western blot.
Conversion of plasminogen to plasmin, and generation of
angiostatin were scored semi-quantitatively, as a combi-
nation of speed of formation and amount of protein
formed, relative to the amount of precursor molecule as
follows:
Plasminogen to plasmin:
1 No conversion at any time point
2 Slight conversion at t = 20 hours
3 Slight conversion at t = 4.5 hours
4 Moderate conversion at t = 4.5 hours
5 Moderate conversion at = 2 hours
6 Considerable conversion at t = 2 hours
7 Complete conversion at t = 2 hours
Plasmin to angiostatin:
1 No conversion
2 Slight conversion
3 Moderate conversion
4 Considerable conversion
5 (Almost) complete conversion
Angiostatin formation in vivo
Healthy BALB/c mice were treated with 0.1 ml 400 mM D-
penicillamine (bidaily intraperitoneal injections) and/or
tPA (i.v. injection, 80 µg in 100 µl saline). Control mice
received saline injections. D-penicillamine administra-
tion was started on day 0, 3 days before the first tPA injec-
tion. Mice received two tPA injections, on day 3 and on
day 7. On day 7, plasma samples were collected prior to
tPA injection (t = 0), and 15 minutes, 2, 4, 8, 24, or 48
hours after tPA injection. Plasminogen, plasmin and angi-
ostatin levels in plasma were determined by western blot
analysis after lysine-sepharose purification.
Purification of angiostatin from plasma by affinity 
chromatography on lysine-sepharose
Lysine-sepharose (Pharmacia Biotech, AB, Uppsala, Sweden)
was prepared according to the manufacturer's specifica-
tions. 50 µl of lysine-sepharose slurry was added to 50 µl
of plasma. After incubation overnight at 4°C under con-
tinuous agitation, samples were washed three times with
50 mM phosphate buffer (pH 6.0), followed by incuba-
tion at room temperature for 30' with 50 µl 0.5 M NaCl to
detach non-specifically bound proteins. Specifically
bound proteins were eluted by incubation for 30' at room
temperature in 50 µl 200 mM ε-aminocapronic acid. After
centrifugation, supernatant was collected, mixed with an
equal volume of sample buffer, and stored at -20°C prior
to western blot analysis.
Generation of rabbit anti-mouse plasminogen polyclonal 
antibody
Mouse plasminogen was isolated from plasma by lysine
sepharose purification. A NZW rabbit was immunized
with plasminogen in complete Freund's adjuvant, fol-
lowed by boosters with mouse plasminogen in PBS every
third week. After three boosters, plasma samples were col-
lected and tested by western blot analysis to determine the
anti-plasminogen antibody titer.
SDS-page and western blot analysis
Western blot analysis to detect angiostatin was performed
as described previously [26]. Briefly, samples were sepa-
rated on 10% polyacrylamide gels under reducing condi-
tions, and electro blotted onto Hybond-C-extra
nitrocellulose membrane (Amersham Life Science bv., Roos-
endaal, The Netherlands). For analysis of plasma samples
from in vivo experiments, a rabbit polyclonal anti-mouse
plasminogen antibody was used (concentration 1: 2000
in blocking solution; our laboratory,[26]), whereas for
assessment of in vitro angiostatin generation a polyclonal
rabbit-anti-human plasminogen antibody (cross-reactive
with mouse plasminogen) was used.
After Incubation with peroxidase conjugated goat-anti-
rabbit antibody (Dako), blots were developed by chemo-
luminescence according to the manufacturer's specifica-
tions (Roche Diagnostics GmbH).
Human melanoma xenograft experiment
Cell line BLM [van Muijen et al., 1991]. was cultured in
Dulbecco's Modified Eagle Medium (DMEM) supple-
mented with glutamine (Biowhittaker, Walkersville, MD,
USA), 10% fetal calf serum (Integro, Zaandam, The Nether-
lands) and antibiotics in plastic culture flasks (Costar,
Roskilde, Denmark). For inoculation, cultured cells were
detached from the culture flask by incubation with 0.05%
trypsin/0,02% EDTA/PBS, washed, and resuspended in
PBS at a concentration of 10 * 106 cells/ml. 1 * 106 Cells
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were injected s.c. in the flank of male 8–10 weeks-old
BALB/c nu/nu mice in a volume of 100 µl. Mice were kept
under aseptic conditions.
D-penicillamine administration (0.1 ml of a 400 mM
solution, twice daily i.p. injection, controls received
saline) was started immediately after tumor take as deter-
mined by palpation of the inoculation site. When
tumours had reached a volume of 100 mm3 (as deter-
mined by length × width × height measurements), intra-
venous tPA injections (0, or 80 µg in 100 µl saline) were
administered 3 times a week, at which time points tumour
volumes were determined as well. Animals were sacrificed
when tumours reached a size of 1000 mm3. Tumours were
removed and stored in liquid nitrogen. In each experi-
ment, at least 5 mice per treatment modality were evalu-
ated. Experiments were repeated three times.
Immunohistochemical staining of blood vessels in human 
melanoma xenografts
Blood vessels were stained immunohistochemically as
described previously (ref Westphal) Briefly, aceton fixed 4
µm cryo tissue sections were incubated overnight at 4°C
with rat-anti-mouse endothelial cell antibody 9F1 (A gen-
erous gift from Dr. A. Hamann, Hamburg, Germany).
Biotinylated rabbit-anti-rat antibody (Vector Laboratories,
Burlingame, CA) followed by avidin-biotin-peroxidase
solution and AEC (Scytek Laboratories, Utah, USA) were
used for detection and color development.
Counting of tumour blood vessels
The number of 9F1 positive blood vessels in melanoma
xenografts was counted in three high-powered fields
(magnification 200×) by two independent researchers
who were blinded for treatment modality as described
previously [32].
Statistical evaluation
Statistical significance was assessed using an one-way
ANOVA. Probability values of 0.05 or less were consid-
ered significant.
Results
Angiostatin generation in vitro
The optimal concentrations for in vitro angiostatin forma-
tion were investigated by incubating murine serum with
uPA, tPA, and/or a free sulfhydryl group donor, followed
by western blot analysis of the reaction products. Figure 1
illustrates a typical experiment, showing conversion of
plasminogen to plasmin and angiostatin by tPA and D-
penicillamine. Incubation of serum with D-penicillamine
alone did not result in any plasmin or angiostatin forma-
tion (figure 1c), whereas incubation with only tPA
resulted in rapid and complete conversion of plasmino-
gen to plasmin, and the formation of a small amount of
angiostatin (figure 1b). Incubation of murine serum with
the combination of D-penicillamine and tPA resulted in
time-dependent formation of considerable amounts of
angiostatin of approximately 36 kDa, and smaller
amounts of angiostatin moieties of 34 and 48 kDa (fig.
1d).
In figure 2 an example of in vitro plasmin and angiostatin
generation by tPA (2 µg/ml) and the different FSDs is
demonstrated. Conversion of plasminogen to plasmin
(left panel) and plasmin to angiostatin (right panel) were
scored separately on a semi-quantitative scale. Compared
In vitro angiostatin generation by tPA and D-penicillamineFigure 1
In vitro angiostatin generation by tPA and D-peni-
cillamine. Murine serum was incubated with tPA, D-peni-
cillamine, or a combination of the two. Reaction products 
were subjected to Western blot analysis employing an anti-
mouse plasminogen antibody. In control samples (a) or sam-
ples incubated with D-penicillamine (c), no conversion of 
plasminogen could be demonstrated. Incubation of serum 
with tPA resulted in the formation of plasmin and a small 
amount of angiostatin (b), whereas substantial amounts of 
angiostatin were observed after incubating serum with both 
tPA and D-penicillamine (d). PLG: plasminogen PLM: plas-
mine ANG: angiostatin
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to the other FSDs D-penicillamine induced the rapid and
effective plasmin and angiostatin generation.
Figure 3 shows a summary of experiments performed to
determine the optimal plasminogen activator (figure 3a
and 3b: tPA, figure 3c and 3d: uPA) and D-penicillamine
concentrations for in vitro angiostatin generation. Conver-
sion of plasminogen to plasmin (figure 3a and 3c) and
plasmin to angiostatin (figure 3b and 3d) were scored as
described above.
D-penicillamine and tPA induced conversion of plas-
minogen to plasmin and plasmin to angiostatin showed a
clear dose-dependency. 2 mM D-penicillamine combined
with 2 µg/ml tPA or more resulted in complete conversion
of plasminogen to plasmin after 2 hours of incubation.
Angiostatin formation was optimal at 4 µg/ml tPA and 20
mM D-penicillamine.
Plasmin generation by uPA in the presence of D-penicilla-
mine was already complete at low uPA (0.02 unit/ml) and
D-penicillamine (0.2 mM) concentrations. Remarkably,
angiostatin formation induced by uPA and D-penicilla-
mine showed an inverse dose-response relationship with
regard to the amount of uPA. Whereas higher D-penicilla-
mine concentrations resulted in the formation of more
angiostatin, increased levels of uPA resulted in less angi-
ostatin formation.
Since angiostatin formation by uPA and D-penicillamine
was subject to inhibition by higher uPA concentrations,
all subsequent in vivo experiments were conducted with
tPA and D-penicillamine.
Angiostatin generation in vivo
To determine whether we could induce angiostatin forma-
tion in vivo, either D-penicillamine (0.1 ml of a 400 mM
solution, bidaily i.p. injections prior to tPA injection), or
tPA (two i.v. injections, 3 days and 7 days after start of the
D-penicillamine/saline injections), or a combination of
the two, were administered to healthy BALB/c mice. After
7 days, plasma samples were collected prior to the tPA
injection (t = 0), and 15 and 120 minutes after tPA injec-
tion. Plasminogen, plasmin, and angiostatin levels were
analyzed by western blot (figure 4).
In plasma from mice receiving only saline injections (fig-
ure 4a) or D-penicillamine (figure 4c), both plasminogen
(110 kDa) and plasmin heavy chain (approximately 70
kDa) were observed in the circulation. No detectable lev-
els of angiostatin were present. In mice receiving only tPA
(figure 4b), an incomplete conversion of plasminogen to
plasmin was observed 15 minutes after tPA injection.
After two hours the levels of plasminogen and plasmin
had returned to normal. The generation of an angiostatin
band at 36 kDa was observed 15 minutes after the tPA
injection. 120 Minutes after tPA injection, no angiostatin
was detectable anymore.
Administration of both tPA and D-penicillamine resulted
in a complete conversion of plasminogen to plasmin, and
formation of angiostatin 15 minutes after tPA injection.
Remarkably, the increased conversion of plasminogen to
plasmin did not result in higher levels of circulating angi-
ostatin compared to injection with tPA alone (figure 4b
vs. 4d). Both plasminogen and angiostatin levels had
returned to normal two hours after tPA injection.
Anti-tumour effect of D-penicillamine/tPA treatment
The anti-tumour effect of D-penicillamine/tPA treatment
was assessed in a human melanoma xenograft model.
Example of in vitro angiostatin generation by tissue-type plas-minogen activator d FSDsFigur  2
Example of in vitro angiostatin generation by tissue-
type plasminogen activator and FSDs. A mixture of 
murine serum, tPA (2 µg/ml) and a FSD (D-penicillamine, L-
cysteine, N-acetyl-L-cysteine (NAC), reduced glutathione, or 
captopril) was incubated for 0, 2, 4.5 or 20 hours. Conver-
sion of plasminogen to plasmin (left panel) and plasmin to 
angiostatin (right panel) were scored separately on a semi-
quantitative scale. D-penicillamine was the most effective 
FSD for generation of plasmin and angiostatin. : 
D-penicillamine;  : L-cysteine;  
: N-acetyl L-ysteine;  : reduced glutathione; 
 : captopril.
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After s.c. injection of human BLM melanoma cells in the
flank, nude mice were treated with D-penicillamine or
saline injections (i.p. injections, twice daily when tumour
take was observed. The tPA or saline injections (i.v. three
times a week) started when tumours reached a size of 100
mm3. Tumour volumes were measured to monitor the
effect of the treatment. Figure 5 shows a representative
example of three different experiments.
In mice receiving only D-penicillamine injections, a small
reduction in tumour growth was observed (23% inhibi-
tion, 17 days after start of treatment), whereas tPA alone
resulted in a 44% reduction in tumour growth. The com-
bination of D-penicillamine and tPA inhibited tumor
growth by 58%. The observed inhibition of tumour
growth, however, was not statistically significant (p =
0.08). In contrast to healthy mice, angiostatin was not
detectable by western blot analysis of plasma samples col-
lected from xenograft-bearing mice treated with tPA and/
or D-penicillamine (data not shown).
Vascular densities of human melanoma xenografts
To determine a possible anti-angiogenic effect of the tPA/
D-penicillamine treatment, blood vessels in melanoma
xenografts were stained with rat-anti-mouse endothelial
cell antibody 9F1 and counted in three high-powered
microscopic fields (figure 6).
The mean number of blood vessels decreased by 34 and
39% in tumours derived from mice treated with only tPA
or D-penicillamine, respectively, compared to tumours
from control mice. Remarkably, the reduction in vessel
density was less in tumours from mice that had been
received the combination treatment (16% compared to
control tumours). All observed reductions in vascular
density were not statistically significant.
Discussion
In a series of recent publications, the positive effect of a
combination of a plasminogen activator (PA) and a free
sulfhydryl group donor (FSD) on in vitro and in vivo angi-
ostatin generation was described. In addition, treatment
with PA plus FSD, or FSD alone, displayed anti-ang-
iogenic and anti-tumour effects in murine xenograft
tumour models [24-26] and in a limited number of
human patients [27]. This novel approach to anti-ang-
iogenic therapy may utilize approved drugs such as capto-
pril as FSD.
In this paper we set out to identify the most potent FSD
with regard to angiostatin generation. In addition, testing
different FSDs with different additional properties next to
donating an SH group, may shed more light on the actual
working mechanism of the anti-angiogenic effects
induced by these drugs.
Our in vitro data demonstrated that, in the presence of
plasminogen activators, all tested FSDs were able to
induce angiostatin generation in vitro, in accordance with
data reported by Gately et al [Gately et al., 1997]. In line
with previous experiments with tPA and captopril? [26],
we observed formation of angiostatin moieties with
molecular weights varying between 30 and 50 kDa under
reducing conditions. The 36 and 48 kDa moieties may
Summary of in vitro angiostatin generation by plasminogen activators and D-penicillamineFigure 3
Summary of in vitro angiostatin generation by plas-
minogen activators and D-penicillamine. Murine serum 
was incubated for 0, 2, 4.5 or 20 hours with D-penicillamine 
and tPA (a and b) or uPA (c and d). Conversion of plasmino-
gen to plasmin (a and c) and plasmin to angiostatin (b and d) 
were scored separately on a semi-quantitative scale. Note 
concentration dependent conversion of plasminogen to plas-
min (a), and conversion of plasmin to angiostatin (b) with 
increasing concentrations of tPA and D-penicillamine (b). 
Surprisingly, uPA was very efficient in plasmin generation (c), 
while with increasing uPA concentrations a reciprocal effect 
on angiostatin formation was observed (d). tPA concentra-
tions (µg/ml): : 0.08;  0.4; 
: 2;  : 4;  : 20 and 
100 uPA concentrations (units/ml):  : 0.004; 
 : 0.02;  : 0.1.
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represent the 3 and 4 kringle forms of angiostatin, respec-
tively. A dose response curve was observed for the angi-
ostatin formation induced by tPA and D-penicillamine.
Remarkably, increasing uPA concentrations in the pres-
ence of FSDs did not result in increased angiostatin levels,
but rather in an inhibition of the formation of this mole-
cule. The reason for this phenomenon was unclear.
Hypothesizing, it could be that (too) high levels of uPA,
cause the activation of negative feedback mechanisms,
resulting in the inactivation of plasmin, and as a conse-
quence in a reduced generation of angiostatin. For this
reason, we decided to perform our in vivo studies with tPA.
Surprisingly, not only angiostatin generation, but also the
conversion of plasminogen to plasmin was enhanced by
FSD addition, suggesting that this first conversion step is,
at least in part, FSD-dependent as well. To our knowledge,
this has never been observed before. In future experi-
ments, we will test this plasmin-activating capacity of
FSDs. Of all tested FSDs, D-penicillamine was, on a molar
basis, most potent in inducing both plasmin and angi-
ostatin formation. Therefore, D-penicillamine was used in
all subsequent in vivo studies.
Although the tPA-induced conversion of plasminogen to
plasmin in vivo was also increased by co-treatment with D-
penicillamine, no increased angiostatin formation com-
pared to treatment with tPA alone was observed. In con-
trast to the multiple molecular weight forms of
angiostatin that we observed in our in vitro experiments, in
vivo only the formation of a single angiostatin species of
36 kDa, comparable to angiostatin generated by tPA and
captopril in previous studies, could be observed. Different
angiostatin moieties might express different anti-ang-
iogenic effects in vivo, although this is at present unclear.
Thus far, only in vitro studies have compared the anti-ang-
iogenic properties of plasminogen fragments containing
kringles 1–3, 1–4, 1–5 and 5 [Cao et al., 2002;Lucas et al.,
1998;Cao et al., 1996].
The fact that plasminogen, plasmin and angiostatin levels
had returned to normal within two hours after the tPA
injection, suggested a relatively short biological T1/2 of
both tPA and angiostatin. Whether angiostatin is subject
to quick renal excretion, is degraded to shorter fragments,
or disappears from the circulation due to other mecha-
nisms, cannot be concluded from our experiments.
When treating mice bearing human melanoma
xenografts, administration with either tPA or D-penicilla-
mine alone resulted in an inhibition of tumour growth
(44% and 23%, respectively). Treatment with both drugs
resulted in a cumulative inhibition (58%). It should be
noted, however, that the observed inhibition of tumour
growth was not statistically significant, and therefore was
far from convincing. In accordance with this finding,
mean vascular densities in treated tumours where some-
what lower than in untreated tumours, but again not sta-
tistically significant. Matsubara et al (1989) [33] found
that D-penicillamine only reduced endothelial cell prolif-
eration in the presence of copper sulfate. Treatment of D-
penicillamine alone did not alter the proliferation. The
lack of administration of copper sulfate during our exper-
iments might be the cause of the somewhat disappointing
in vivo effects. However, Matsubara et al (1989) [33] also
In vivo angiostatin formation in healthy mice after treatment with tPA and/or D-penic llamineFigure 4
In vivo angiostatin formation in healthy mice after 
treatment with tPA and/or D-penicillamine. In vivo 
angiostatin generation was induced by administration of tPA 
(two i.v. injections, on day 3 and 7) and/or D-penicillamine 
(i.p. injection, twice daily, starting prior to the first tPA injec-
tion) to healthy BALB/c mice. Plasma samples were collected 
prior to the tPA injection on day 7 (t = 0), and 15 or 120 
minutes after tPA injection. After purification by lysine sepha-
rose affinity chromatography, samples were analyzed on 
western blot. Note a complete conversion of plasminogen to 
plasmin, and the formation of angiostatin in mice receiving 
tPA and D-penicillamine, 15 minutes after tPA injection.
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treated rabbits with D-penicilamine, and these experi-
ments did result into inhibition of vessels growth in the
cornea. But their administration route was intravenously,
and not intraperitoneal as our route was. This could made
the differences in the anti-angiogenic effects of D-peni-
cillamine observed in both experiments.
In contrast to our D-penicillamine data, co-administra-
tion of captopril to mice treated with tPA in similar exper-
iments, resulted in a clearly enhanced formation of
angiostatin, and in a significant inhibition of tumour
growth [26]. We therefore concluded that the superior
capacity of D-penicillamine to induce angiostatin forma-
tion in vitro compared to captopril and other FSDs, was
antagonized by environmental factors present in the liv-
ing organism, resulting in a failure to significantly inhibit
tumour growth.
Several explanations for this finding can be offered. Both
captopril and D-penicillamine possess other characteris-
tics that may influence angiogenesis and tumour growth.
First, as discussed previously, the drop in blood pressure
induced by captopril-mediated ACE inhibition may
account for some of its anti-tumour activity. D-penicilla-
mine does not alter blood pressure.
Second, captopril may inhibit MMP function, thus pre-
venting angiogenesis. D-penicillamine, on the other
hand, does not affect blood pressure, but might share with
captopril the ability to inhibit MMPs, by chelating metal
ions. MMPs require zinc to express their activity. There-
fore, chelation of these zinc molecules by D-penicillamine
prevents the activation of MMPs. Moreover, it is known
Anti-tumor effects of tPA and D-penicillamine in a human melano a x nograft modelFigure 5
Anti-tumor effects of tPA and D-penicillamine in a 
human melanoma xenograft model. Nude mice 
xenografted with human melanoma BLM were treated with 
tPA, D-penicillamine, or a combination of tPA and D-peni-
cillamine. Shown are mean tumor volumes of at least 5 mice/
treatment modality plus/minus SD. A reduction in tumor 
growth of 58% was observed by applying the combination 
treatment schedule. Treatment schedules:  : 
none;  : D-penicillamine;  : tPA; 
: tPA and D-penicillamine
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Treatment effects on the amount of tumor vesselsFigure 6
Treatment effects on the amount of tumor vessels. In 
tissue sections from BLM tumors derived from mice treated 
with tPA and/or D-penicillamine, blood vessels were stained 
with rat-anti-mouse-endothelial cell antibody 9F1, and quan-
tified. Although a reduction in vessel density was observed 
after either treatment, these reductions did not reach statis-
tical significance.
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that D-penicillamine suppresses the inhibitory effects of
hypochlorous acid (HOCl) on TIMP-1 (tissue inhibitor of
metalloproteinase-1). As a consequence, TIMP-1 is not
inhibited anymore, and could express its activity: limiting
MMP activity [34].
Third, the fact that D-penicillamine binds with high affin-
ity to albumin [35,36] migt be of importance. By binding
to albumin, the bioavailability, and therefore efficacy, of
free circulating D-penicillamine is reduced. D-penicilla-
mine sequestered to albumin may be less capable, or even
unable, to donate its SH groups.
The fact that we could not detect angiostatin in tumour-
bearing mice treated with tPA or tPA plus D-penicillamine
suggested that circulating angiostatin is taken up by the
tumour, for instance by binding of angiostatin to tumour
blood vessels. As, however, immunohistochemical stain-
ing for angiostatin requires a specific antibody that does
not stain the precursor (plasminogen) and this is not
available, this could not be confirmed.
Another explanation for the absence of angiostatin could
be that other anti-angiogenic factors might be present in
our model. In our studies with tPA and captopril [26], and
D-penicillamine (this paper), as well as in the study pub-
lished by Agarwal with N-acetyl-cysteine (NAC), it is
unclear whether angiostatin was in fact the effector mole-
cule responsible for the observed anti-angiogenic and
anti-tumour effects. Although Agarwal described accumu-
lation of angiostatin in tumors derived from mice treated
with NAC, no depletion studies were performed.
Agarwal et al. only administered the FSD N-acetyl-cysteine
to achieve anti-angiogenic and anti-tumour activity, with-
out the need for additional plasminogen activator admin-
istration. In vitro it was shown that tumour-derived VEGF
induced expression of uPA and uPAR on HUVEC. In addi-
tion, uPA and uPAR expression was also demonstrated on
tumour endothelium of NAC-treated mice. Apparently,
this endothelium-derived uPA was sufficient to produce
angiostatin. This notion is supported by our observations
that both captopril and D-penicillamine are able to
induce some (although not significant) inhibition of
tumour growth. Additionally, captopril alone has been
shown to possess anti-tumour activity in a human Karposi
sarcoma patient [37], and in murine tumour models
[38,28,29].
Furthermore, plasminogen activators expressed by the
tumours used in these experiments, may have contributed
to the observed anti-tumour effects after treatment with
captopril or D-penicillamine alone. The human
melanoma cell line BLM we used in our xenograft growth
inhibition experiments expresses high levels of tPA. In
both cases, however, administration of exogenous tPA
improved anti-tumour activity, suggesting that the efficacy
of the N-acetyl-cysteine treatment as reported by Agarwal
may benefit from administration of exogenous plasmino-
gen activators as well.
Conclusion
In conclusion, recent studies have provided evidence that
upregulation of endogenous anti-angiogenic molecules as
a novel anti-tumour therapy is feasible. Further studies are
required to identify the most efficient plasminogen activa-
tors and FSDs, their optimal concentrations, and the
appropriate application strategies. Regarding the dramati-
cally different angiostatin generating capacities of D-pen-
icillamine in vitro versus in vivo, our results indicate that
selecting the most appropriate free sulfhydryl donor for
anti-angiogenic therapy in a (pre)clinical setting should
be performed by in vivo rather than by in vitro studies.
Finally, we conclude that D-penicillamine is not suitable
for this type of therapy.
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